The cooling device at the tip of the ultrasound transducer helps reduce discomfort as well
Dallas, TX, April 22, 2025 (GLOBE NEWSWIRE) -- Wondr Health, the proven and trusted leader in digital, evidence-based lifestyle support and behavior-change interventions for full-spectrum weight and obesity management, today announced expansions to its comprehensive metabolic health programs to help employers prevent and manage the most common and expensive weight-related chronic health conditions while mitigating the financial risks associated with GLP-1 coverage
lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diabetes Care, and Sanofi
Phase 2 body composition substudy data using DEXA scans showed that retatrutide participants lost predominantly fat mass, with a favorable fat-to-lean mass loss ratio
Human Topical Evidence The most consumer-relevant tier of evidence actual clinical trials in humans is also the most variable
While needles remain an important barrier for some, our research shows theyre far from the only reason people arent using GLP-1 treatments